Home › Funds › Newtyn Management, LLC › TBPH
Newtyn Management, LLC position in TBPH
THERAVANCE BIOPHARMA INC
Newtyn Management, LLC reported holding 3,434,191 shares of TBPH (THERAVANCE BIOPHARMA INC) in its Q2 2026 13F filing — a position valued at US$58.4M, representing 7.29% of its reported portfolio and ranking #2 among its reported holdings. Newtyn Management, LLC has disclosed TBPH holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Newtyn Management, LLC's TBPH position evolved
Newtyn Management, LLC first disclosed a stake in TBPH in Q3 2023 at 1,841,560 shares (US$15.9M). The position peaked in Q4 2025 at 4,300,000 shares, worth US$80.5M. Across 12 filings, Newtyn Management, LLC increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 3,434,191 shares valued at US$58.4M — a reduction of -1,407,438 shares quarter over quarter.. Notable position changes include a 29% increase in Q2 2024, a 112% increase in Q3 2024, a 29% trim in Q2 2026.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.84M | $15.89M | New |
| Q4 2023 | 1.90M | $21.36M | Add |
| Q1 2024 | 1.64M | $14.75M | Reduce |
| Q2 2024 | 2.12M | $18.02M | Add |
| Q3 2024 | 4.50M | $36.26M | Add |
| Q4 2024 | 4.76M | $44.77M | Add |
| Q1 2025 | 4.76M | $42.48M | Hold |
| Q2 2025 | 4.95M | $54.60M | Add |
| Q3 2025 | 4.95M | $72.27M | Hold |
| Q4 2025 | 4.30M | $80.45M | Reduce |
| Q1 2026 | 4.84M | $78.58M | Add |
| Q2 2026 | 3.43M | $58.38M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TBPH and 13F data
TBPH (THERAVANCE BIOPHARMA INC) is a company whose sector is not yet classified in our data. 31 other funds we track also report a position in TBPH — the largest reported positions include Madison Avenue Partners, LP (US$156.6M), Weiss Asset Management LP (US$126.8M), Irenic Capital Management LP (US$46.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TBPH
- Madison Avenue Partners, LP 9.21M sh · $156.61M · Q2 2026
- Weiss Asset Management LP 7.46M sh · $126.77M · Q2 2026
- Irenic Capital Management LP 2.76M sh · $46.94M · Q2 2026
- Oasis Management Co Ltd. 583.49K sh · $9.92M · Q2 2026
More on Newtyn Management, LLC
FAQ
How long has Newtyn Management, LLC held TBPH?
Newtyn Management, LLC has disclosed TBPH holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Newtyn Management, LLC's current position in TBPH?
As of Q2 2026, Newtyn Management, LLC holds 3.43M shares of TBPH (THERAVANCE BIOPHARMA INC), valued at $58.38M, representing 7.29% of its reported portfolio and ranking #2.
Has Newtyn Management, LLC been buying or selling TBPH?
In the latest 13F filing (Q2 2026), Newtyn Management, LLC reduced its position in TBPH. The position peaked in Q4 2025 at 4.30M shares.
Which other funds hold TBPH?
Other major institutional holders of TBPH include Madison Avenue Partners, LP, Weiss Asset Management LP, Irenic Capital Management LP, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.